Results 171 to 180 of about 612,525 (237)

Pindel-TD: A Tandem Duplication Detector Based on A Pattern Growth Approach. [PDF]

Genomics Proteomics Bioinformatics
Yang X, Zheng G, Jia P, Wang S, Ye K.
europepmc   +1 more source

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001 [PDF]

, 2017
Uy, Geoffrey L., Westervelt, Peter
core   +1 more source

Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia. [PDF]

Clin Transl Sci
Vaddady P, Smania G, Nakayama S, Inoue H, Kurumaddali A, Abutarif M, Zheng M.   +6 more
europepmc   +1 more source

Homozygous, Intragenic Tandem Duplication of SFTPB Causes Neonatal Respiratory Failure. [PDF]

Am J Respir Cell Mol Biol
Wambach JA, Wegner DJ, Kitzmiller J, White FV, Heins HB, Yang P, Paul AJ, Granadillo JL, Eghtesady P, Kuklinski C, Turner T, Fairman K, Stone K, Wilson T, Breman A, Smith J, Schroeder MC, Neidich JA, Whitsett JA, Cole FS.   +19 more
europepmc   +1 more source

Detection of KMT2A Partial Tandem Duplication by Optical Genome Mapping in Myeloid Neoplasms: Associated Cytogenetics, Gene Mutations, Treatment Responses, and Patient Outcomes. [PDF]

Cancers (Basel)
Wei Q, Hu S, Xu J, Loghavi S, Daver N, Toruner GA, Wang W, Medeiros LJ, Tang G.   +8 more
europepmc   +1 more source

Next-generation sequencing of duplication CNVs reveals that most are tandem and some create fusion genes at breakpoints.

American Journal of Human Genetics, 2015
S. Newman, Karen E. Hermetz, Brooke Weckselblatt, M. K. Rudd   +3 more
semanticscholar   +1 more source

Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia. [PDF]

Cancers (Basel)
Seto A, Downs G, King O, Salehi-Rad S, Baptista A, Chin K, Grenier S, Nwachukwu B, Tierens A, Minden MD, Smith AC, Capo-Chichi JM.   +11 more
europepmc   +1 more source

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Journal of Clinical Oncology, 2013
J. Cortes, H. Kantarjian, J. Foran, D. Ghirdaladze, M. Zodelava, G. Borthakur, G. Gammon, D. Trone, R. Armstrong, J. James, M. Levis   +10 more
semanticscholar   +1 more source

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Blood, 2013
F. Ravandi, M. Alattar, M. Grunwald, M. Rudek, T. Rajkhowa, M. Richie, S. Pierce, N. Daver, G. Garcia-Manero, S. Faderl, A. Nazha, M. Konopleva, G. Borthakur, J. Burger, T. Kadia, S. Dellasala, M. Andreeff, J. Cortes, H. Kantarjian, M. Levis   +19 more
semanticscholar   +1 more source

Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study. [PDF]

Cancer
Gyan E, Minden MD, Kubo K, Rambaldi A, Juliusson G, Jädersten M, Kelly RJ, Szerafin L, He W, Gill SC, Hill JE, Chen C, Delgado D, Hasabou N.   +13 more
europepmc   +1 more source